These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 25406295)

  • 41. Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context.
    Hope R; Blackburn RM; Verlander NQ; Johnson AP; Kearns A; Hill R; Hopkins S; Sheridan E; Livermore DM; ;
    J Antimicrob Chemother; 2013 Nov; 68(11):2641-7. PubMed ID: 23794604
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.
    Biedenbach DJ; Hoban DJ; Reiszner E; Lahiri SD; Alm RA; Sahm DF; Bouchillon SK; Ambler JE
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7873-7. PubMed ID: 26416860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.
    Kan LP; Lin JC; Chiu SK; Yeh YC; Lin TY; Yang YS; Wang YC; Wang NC; Yeh KM; Chang FY
    J Microbiol Immunol Infect; 2014 Feb; 47(1):15-22. PubMed ID: 23040238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
    BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
    Kebriaei R; Rice SA; Stamper KC; Rybak MJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China.
    Chang W; Ma X; Gao P; Lv X; Lu H; Chen F
    Indian J Med Microbiol; 2015; 33(2):262-6. PubMed ID: 25865979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of ceftaroline and ceftobiprole against methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin isolated in paediatric patients.
    Carnesecchi G; Lobello R; Liggieri L; Palmero C; Pescetto L; Morelli P; Castagnola E; Bandettini R
    J Chemother; 2018; 30(6-8):338-341. PubMed ID: 30375268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC.
    Chong YP; Park SJ; Kim HS; Kim ES; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS
    Diagn Microbiol Infect Dis; 2012 Jul; 73(3):264-6. PubMed ID: 22621914
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus.
    García AB; Candel FJ; López L; Chiarella F; Viñuela-Prieto JM
    J Med Microbiol; 2016 Oct; 65(10):1119-1122. PubMed ID: 27553740
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals.
    Alfouzan W; Boswihi SS; Dhar R; Udo E
    J Infect Public Health; 2020 Oct; 13(10):1589-1591. PubMed ID: 32859552
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective.
    Alm RA; McLaughlin RE; Kos VN; Sader HS; Iaconis JP; Lahiri SD
    J Antimicrob Chemother; 2014 Aug; 69(8):2065-75. PubMed ID: 24777906
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.
    Falcón R; Mateo E; Oltra R; Giménez E; Albert E; Torres I; Navarro D
    Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):903-912. PubMed ID: 30729396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of ceftaroline against mecC-positive MRSA isolates.
    Armengol-Porta M; Tenorio-Abreu A; Bandt D; Coleman DC; Gavier-Widen D; Hotzel H; Kinnevey P; Lazaris A; Peters M; Rangstrup-Christensen L; Schlotter K; Shore AC; Ehricht R; Monecke S
    J Glob Antimicrob Resist; 2016 Jun; 5():3-6. PubMed ID: 27436457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
    Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
    Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus.
    Hutton MA; Sundaram A; Perri MB; Zervos MJ; Herc ES
    Diagn Microbiol Infect Dis; 2020 Nov; 98(3):115126. PubMed ID: 32861155
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.